Brief: Allarity To Focus On Accelerating Stenoparib Toward Regulatory Approval In Advanced Recurrent Ovarian Cancer
27/03/2024 12:42
March 27 (Reuters) - Allarity Therapeutics Inc ALLR.O :
* ALLARITY THERAPEUTICS MAKES STRATEGIC PIVOT TO FOCUS
SOLELY ON
ACCELERATING STENOPARIB TOWARD REGULATORY APPROVAL IN ADVANCED
RECURRENT OVARIAN CANCER
* ALLARITY THERAPEUTICS INC: STENOPARIB PHASE 2 MONOTHERAPY
TRIAL
IN ADVANCED, RECURRENT OVARIAN CANCER CONTINUES TO SHOW PROMISE
* ALLARITY THERAPEUTICS INC: FURTHER DEVELOPMENT OF
IXEMPRA(®) AND
DOVITINIB IS DE-PRIORITIZED
* ALLARITY THERAPEUTICS INC: HAS BEEN ABLE TO REDUCE COSTS
MATERIALLY
Source text for Eikon: ID:nGNX83YBhs
Further company coverage: ALLR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic